BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Asif-Malik A, Hoener MC, Canales JJ. Interaction Between the Trace Amine-Associated Receptor 1 and the Dopamine D2 Receptor Controls Cocaine's Neurochemical Actions. Sci Rep 2017;7:13901. [PMID: 29066851 DOI: 10.1038/s41598-017-14472-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Dedic N, Dworak H, Zeni C, Rutigliano G, Howes OD. Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies. IJMS 2021;22:13185. [DOI: 10.3390/ijms222413185] [Reference Citation Analysis]
2 Synan C, Bowen C, Heal DJ, Froger-Colléaux C, Beardsley PM, Dedic N, Hopkins SC, Campbell U, Koblan KS. Ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and attenuates cocaine cue-induced relapse in rats. Drug Alcohol Depend 2021;231:109261. [PMID: 35033729 DOI: 10.1016/j.drugalcdep.2021.109261] [Reference Citation Analysis]
3 Klein MO, Battagello DS, Cardoso AR, Hauser DN, Bittencourt JC, Correa RG. Dopamine: Functions, Signaling, and Association with Neurological Diseases. Cell Mol Neurobiol 2019;39:31-59. [PMID: 30446950 DOI: 10.1007/s10571-018-0632-3] [Cited by in Crossref: 134] [Cited by in F6Publishing: 104] [Article Influence: 33.5] [Reference Citation Analysis]
4 Liu J, Wu R, Seaman R, Manz KM, Johnson B, Vu J, Huang Y, Zhang Y, Robison AJ, Neve R, Grueter BA, Dietz D, Li J. TAAR1 regulates drug-induced reinstatement of cocaine-seeking via negatively modulating CaMKIIα activity in the NAc. Mol Psychiatry. [DOI: 10.1038/s41380-022-01448-3] [Reference Citation Analysis]
5 Chen R, Ferris MJ, Wang S. Dopamine D2 autoreceptor interactome: Targeting the receptor complex as a strategy for treatment of substance use disorder. Pharmacol Ther 2020;213:107583. [PMID: 32473160 DOI: 10.1016/j.pharmthera.2020.107583] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Cosín-Roger J, Ortiz-Masia D, Barrachina MD, Calatayud S. Metabolite Sensing GPCRs: Promising Therapeutic Targets for Cancer Treatment? Cells 2020;9:E2345. [PMID: 33113952 DOI: 10.3390/cells9112345] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Dorotenko A, Tur M, Dolgorukova A, Bortnikov N, Belozertseva IV, Zvartau EE, Gainetdinov RR, Sukhanov I. The Action of TAAR1 Agonist RO5263397 on Executive Functions in Rats. Cell Mol Neurobiol 2020;40:215-28. [PMID: 31734895 DOI: 10.1007/s10571-019-00757-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Kostrzewa RM, Wydra K, Filip M, Crawford CA, McDougall SA, Brown RW, Borroto-Escuela DO, Fuxe K, Gainetdinov RR. Dopamine D2 Receptor Supersensitivity as a Spectrum of Neurotoxicity and Status in Psychiatric Disorders. J Pharmacol Exp Ther 2018;366:519-26. [PMID: 29921706 DOI: 10.1124/jpet.118.247981] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
9 Gainetdinov RR, Hoener MC, Berry MD. Trace Amines and Their Receptors.Pharmacol Rev. 2018;70:549-620. [PMID: 29941461 DOI: 10.1124/pr.117.015305] [Cited by in Crossref: 98] [Cited by in F6Publishing: 82] [Article Influence: 24.5] [Reference Citation Analysis]
10 Wu R, Li JX. Potential of Ligands for Trace Amine-Associated Receptor 1 (TAAR1) in the Management of Substance Use Disorders. CNS Drugs 2021;35:1239-48. [PMID: 34766253 DOI: 10.1007/s40263-021-00871-4] [Reference Citation Analysis]
11 Schwartz MD, Canales JJ, Zucchi R, Espinoza S, Sukhanov I, Gainetdinov RR. Trace amine-associated receptor 1: a multimodal therapeutic target for neuropsychiatric diseases. Expert Opinion on Therapeutic Targets 2018;22:513-26. [DOI: 10.1080/14728222.2018.1480723] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
12 Wu R, Liu J, Johnson B, Huang Y, Zhang Y, Li JX. Activation of trace amine-associated receptor 1 attenuates nicotine withdrawal-related effects. Addict Biol 2022;27:e13075. [PMID: 34170054 DOI: 10.1111/adb.13075] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Kantrowitz JT. Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions. CNS Drugs 2021;35:1153-61. [PMID: 34655036 DOI: 10.1007/s40263-021-00864-3] [Reference Citation Analysis]
14 Liu J, Wu R, Li JX. TAAR1 and Psychostimulant Addiction. Cell Mol Neurobiol 2020;40:229-38. [PMID: 31974906 DOI: 10.1007/s10571-020-00792-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
15 Sukhanov I, Dorofeikova M, Dolgorukova A, Dorotenko A, Gainetdinov RR. Trace Amine-Associated Receptor 1 Modulates the Locomotor and Sensitization Effects of Nicotine. Front Pharmacol 2018;9:329. [PMID: 29681856 DOI: 10.3389/fphar.2018.00329] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
16 Mantas I, Vallianatou T, Yang Y, Shariatgorji M, Kalomoiri M, Fridjonsdottir E, Millan MJ, Zhang X, Andrén PE, Svenningsson P. TAAR1-Dependent and -Independent Actions of Tyramine in Interaction With Glutamate Underlie Central Effects of Monoamine Oxidase Inhibition. Biol Psychiatry 2021;90:16-27. [PMID: 33579534 DOI: 10.1016/j.biopsych.2020.12.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
17 Rickli A, Hoener MC, Liechti ME. Pharmacological profiles of compounds in preworkout supplements ("boosters"). Eur J Pharmacol 2019;859:172515. [PMID: 31265842 DOI: 10.1016/j.ejphar.2019.172515] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
18 Shi X, Swanson TL, Miner NB, Eshleman AJ, Janowsky A. Activation of Trace Amine-Associated Receptor 1 Stimulates an Antiapoptotic Signal Cascade via Extracellular Signal-Regulated Kinase 1/2. Mol Pharmacol 2019;96:493-504. [PMID: 31409621 DOI: 10.1124/mol.119.116798] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Martel JC, Gatti McArthur S. Dopamine receptor subtypes, Physiology and pharmacology: New ligands and concepts in schizophrenia. Front Pharmacol. 2020;11:1003. [PMID: 32765257 DOI: 10.3389/fphar.2020.01003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 11.5] [Reference Citation Analysis]
20 Kong Q, Zhang H, Wang M, Zhang J, Zhang Y. The TAAR1 inhibitor EPPTB suppresses neuronal excitability and seizure activity in mice. Brain Res Bull 2021;171:142-9. [PMID: 33811954 DOI: 10.1016/j.brainresbull.2021.03.018] [Reference Citation Analysis]